CagriSema: Novo's Answer to the Triple-Agonist Era

The setup

With Lilly's retatrutide posting 28.7% weight loss in Phase 3, the question became: what is Novo Nordisk's answer?

Novo's bet is CagriSema — a two-drug combination of their existing flagship (semaglutide) plus a novel amylin-receptor agonist (cagrilintide). Rather than building a triple-agonist molecule from scratch, Novo is layering two single-agonist drugs with complementary mechanisms.

What is cagrilintide?

Cagrilintide is a long-acting amylin and calcitonin receptor agonist. It's a modified version of amylin — a pancreatic hormone co-secreted with insulin that acts as a "second satiety hormone."

When you eat, your pancreas releases insulin (you've heard of this) and amylin (you probably haven't). Amylin:

• Slows gastric emptying
• Reduces glucagon secretion
• Acts on the brainstem to reduce food intake

Natural amylin has a half-life of about 13 minutes. Cagrilintide is engineered with fatty acid modifications to extend that to ~7 days — matching semaglutide's dosing cadence. Same needle. Same day. One weekly injection.

Why combine amylin + GLP-1?

Different receptors. Different cellular pathways. Overlapping outcomes.

• GLP-1 acts primarily on L-cell-derived pathways
• Amylin acts primarily on pancreatic β-cell-derived pathways
• The combination activates two satiety systems simultaneously

The mechanistic prediction: combining them should produce additive (possibly synergistic) weight loss with less side-effect burden than maxing out either individually. REDEFINE 1 confirms this.

REDEFINE 1 Phase 3 results

What REDEFINE 1 suggests

Lean-mass preservation. Preliminary body composition data from REDEFINE 1 suggest CagriSema may preserve lean mass better than semaglutide monotherapy. If this holds up in follow-up publications, it addresses one of the biggest criticisms of GLP-1 therapy — that 25–40% of weight loss is muscle.

Better tolerability at higher effect. The Phase 2 data suggested CagriSema had similar or lower GI side-effect burden than semaglutide alone — despite producing more weight loss. The mechanistic explanation: distributing the "satiety dose" across two pathways rather than maxing one.

Cardiometabolic markers. A1C dropped ~1.6% in the diabetic subgroup. Blood pressure, triglycerides, liver enzymes all improved.

CagriSema vs retatrutide

This is the comparison everyone wants:

Retatrutide is the stronger molecule. CagriSema is the more practical molecule. The comparison is roughly:

• Retatrutide = 28.7% weight loss, newer class, more unknowns
• CagriSema = 22.7% weight loss, semaglutide's safety record + a new partner

Real-world, both are likely to find patient populations. CagriSema's story is "sema but better tolerated." Retatrutide's is "the most powerful obesity drug we've ever made."

The amylin story beyond CagriSema

Cagrilintide itself as a monotherapy is being studied. Phase 2 showed ~11% weight loss. That's meaningful — roughly the same as older GLP-1s like liraglutide. If approved independently, it would be a useful second-line option for patients who don't tolerate GLP-1s.

Novo is also running AM833 (cagrilintide's development name) in trials for obesity + NASH, type 2 diabetes, and other indications.

Tolerability and side effects

As with any GLP-1-class therapy:

The 2026 regulatory path

Novo's expected submission timeline:

• Phase 3 full readouts (multiple arms): Q2 2026
• NDA filing: Q3 2026
• FDA review: standard 10-month (could be accelerated)
• Potential approval: Q3–Q4 2027

This lags retatrutide by ~1 year. Both drugs will compete in the market, but the real battle may be who combination therapy works best for — Novo's approach (cagrilintide + semaglutide), or Lilly's (orforglipron + cagrilintide, or retatrutide alone as monotherapy).

Bottom line for researchers

• CagriSema is real — Phase 3 data replicates Phase 2 signal
• Semaglutide is not dead — it's the foundation of Novo's next drug
• Amylin signaling is a durable, separate target — expect cagrilintide and related molecules in multiple future combinations
• Cost will matter — CagriSema is two molecules in one injection. Pricing will reflect that.